Fuji Pharma Valuation

Is 4554 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4554 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4554 (¥1533) is trading below our estimate of fair value (¥2451.59)

Significantly Below Fair Value: 4554 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4554?

Other financial metrics that can be useful for relative valuation.

4554 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.4x
Enterprise Value/EBITDA9.2x
PEG Ratio-0.6x

Price to Earnings Ratio vs Peers

How does 4554's PE Ratio compare to its peers?

The above table shows the PE ratio for 4554 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average14x
4577 Daito PharmaceuticalLtd
10.7xn/aJP¥35.3b
4548 Seikagaku
22.4x12.1%JP¥47.9b
4886 ASKA Pharmaceutical HoldingsLtd
9x-4.3%JP¥68.0b
4552 JCR Pharmaceuticals
14.1x4.9%JP¥75.6b
4554 Fuji Pharma
6.3x-10.0%JP¥36.4b

Price-To-Earnings vs Peers: 4554 is good value based on its Price-To-Earnings Ratio (6.3x) compared to the peer average (14x).


Price to Earnings Ratio vs Industry

How does 4554's PE Ratio compare vs other companies in the JP Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a13.6%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a13.6%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 4554 is good value based on its Price-To-Earnings Ratio (6.3x) compared to the JP Pharmaceuticals industry average (18.7x).


Price to Earnings Ratio vs Fair Ratio

What is 4554's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4554 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio6.3x
Fair PE Ratio11.4x

Price-To-Earnings vs Fair Ratio: 4554 is good value based on its Price-To-Earnings Ratio (6.3x) compared to the estimated Fair Price-To-Earnings Ratio (11.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4554 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentJP¥1,533.00
JP¥2,056.67
+34.2%
3.9%JP¥2,170.00JP¥2,000.00n/a3
Jul ’25JP¥1,478.00
JP¥2,056.67
+39.2%
3.9%JP¥2,170.00JP¥2,000.00n/a3
Jun ’25JP¥1,485.00
JP¥2,056.67
+38.5%
3.9%JP¥2,170.00JP¥2,000.00n/a3
May ’25JP¥1,596.00
JP¥2,090.00
+31.0%
6.1%JP¥2,270.00JP¥2,000.00n/a3
Apr ’25JP¥1,635.00
JP¥2,156.67
+31.9%
5.3%JP¥2,270.00JP¥2,000.00n/a3
Mar ’25JP¥1,703.00
JP¥2,156.67
+26.6%
5.3%JP¥2,270.00JP¥2,000.00n/a3
Feb ’25JP¥1,986.00
JP¥2,156.67
+8.6%
5.3%JP¥2,270.00JP¥2,000.00n/a3
Jan ’25JP¥1,739.00
JP¥2,135.00
+22.8%
6.3%JP¥2,270.00JP¥2,000.00n/a2
Dec ’24JP¥1,536.00
JP¥1,915.00
+24.7%
4.4%JP¥2,000.00JP¥1,830.00n/a2
Nov ’24JP¥1,174.00
JP¥1,915.00
+63.1%
4.4%JP¥2,000.00JP¥1,830.00n/a2
Oct ’24JP¥1,166.00
JP¥1,785.00
+53.1%
12.0%JP¥2,000.00JP¥1,570.00n/a2
Sep ’24JP¥1,178.00
JP¥1,835.00
+55.8%
14.4%JP¥2,100.00JP¥1,570.00n/a2
Aug ’24JP¥1,189.00
JP¥1,835.00
+54.3%
14.4%JP¥2,100.00JP¥1,570.00n/a2
Jul ’24JP¥1,163.00
JP¥1,835.00
+57.8%
14.4%JP¥2,100.00JP¥1,570.00JP¥1,478.002
Jun ’24JP¥1,144.00
JP¥1,835.00
+60.4%
14.4%JP¥2,100.00JP¥1,570.00JP¥1,485.002
May ’24JP¥1,245.00
JP¥1,835.00
+47.4%
14.4%JP¥2,100.00JP¥1,570.00JP¥1,596.002
Apr ’24JP¥1,133.00
JP¥1,835.00
+62.0%
14.4%JP¥2,100.00JP¥1,570.00JP¥1,635.002
Mar ’24JP¥1,067.00
JP¥1,680.00
+57.5%
13.1%JP¥1,900.00JP¥1,460.00JP¥1,703.002
Feb ’24JP¥1,052.00
JP¥1,680.00
+59.7%
13.1%JP¥1,900.00JP¥1,460.00JP¥1,986.002
Jan ’24JP¥1,023.00
JP¥1,680.00
+64.2%
13.1%JP¥1,900.00JP¥1,460.00JP¥1,739.002
Dec ’23JP¥1,013.00
JP¥1,680.00
+65.8%
13.1%JP¥1,900.00JP¥1,460.00JP¥1,536.002
Nov ’23JP¥1,051.00
JP¥1,640.00
+56.0%
15.9%JP¥1,900.00JP¥1,380.00JP¥1,174.002
Oct ’23JP¥1,034.00
JP¥1,640.00
+58.6%
15.9%JP¥1,900.00JP¥1,380.00JP¥1,166.002
Sep ’23JP¥1,020.00
JP¥1,640.00
+60.8%
15.9%JP¥1,900.00JP¥1,380.00JP¥1,178.002
Aug ’23JP¥1,005.00
JP¥1,540.00
+53.2%
10.4%JP¥1,700.00JP¥1,380.00JP¥1,189.002
Jul ’23JP¥959.00
JP¥1,540.00
+60.6%
10.4%JP¥1,700.00JP¥1,380.00JP¥1,163.002

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.